PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer

Molecular Cancer Research

Volumn 10, Issue 12, 2012, Pages 1555-1566

  Hockla, Alexandra ^a   Miller, Erin ^a   Salameh, Moh'd A ^a   Copland, John A ^a   Radisky, Derek C ^a   Radisky, Evette S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTRYPSIN; TRYPSIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DEGRADATION; PROTEIN MICROARRAY; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; GENE SILENCING; HUMANS; MALE; MICE; MICE, INBRED NOD; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; PROGNOSIS; PROSTATIC NEOPLASMS; TRYPSIN; TRYPSIN INHIBITORS; UP-REGULATION;

EID: 84871365923     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0314     Document Type: Article

References (59)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16. (Pubitemid 39665537)
3. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9. (Pubitemid 41124175)
4. Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel HR. The metastatic cascade in prostate cancer. Surg Oncol 2006;15:117-28. (Pubitemid 46241866)
5. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-speci fi c colonization. Nat Rev Cancer 2009;9:274-84.
6. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239 -52.
7. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
8. Radisky ES, Radisky DC. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 2007;8:279-87. (Pubitemid 47524870)
9. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010;15:201-12.
10. Jiang G, Cao F, Ren G, Gao D, Bhakta V, Zhang Y, et al. PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut 2010;59:1535-44.
11. Cottrell GS, Amadesi S, Grady EF, Bunnett NW. Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem 2004;279:13532-9. (Pubitemid 38468878)
12. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999;96:11054-61. (Pubitemid 29487326)
13. Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 2004;64:5564-9. (Pubitemid 39095550)
14. Yang L, Zhang L, Wu Q, Boyd DD. Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets. J Biol Chem 2008;283:35295-304.
15. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16- 23.
16. Dozmorov MG, Hurst RE, Culkin DJ, Kropp BP, Frank MB, Osban J, et al. Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate 2009;69:1077-90.
17. Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES. The P(2)′ residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity. Biochem J 2011;440:95-105.
18. Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 2005;280:31109-15. (Pubitemid 41291846)
19. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997;18:1215- 23.
20. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007;4:359-65. (Pubitemid 46766981)
21. Salameh MA, Soares AS, Hockla A, Radisky ES. Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin. J Biol Chem 2008;283:4115-23.
22. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406. (Pubitemid 41579834)
23. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007;7:64.
24. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression pro filing identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6. (Pubitemid 38121040)
25. Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat 2010;124:27-38.
26. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 1984;44:3522-9. (Pubitemid 14098607)
27. Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, Helenowski I, et al. Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 2008;68:2024-32. (Pubitemid 351416590)
28. Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999;59:1987-93. (Pubitemid 29186176)
29. Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, et al. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 2001;47:1-13. (Pubitemid 32246747)
30. Salameh MA, Soares AS, Navaneetham D, Sinha D, Walsh PN, Radisky ES. Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin. J Biol Chem 2010;285:36884-96.
31. Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 1997;18:1225-31. (Pubitemid 28132514)
32. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88:2989-94. (Pubitemid 30413181)
33. Salameh MA, Robinson JL, Navaneetham D, Sinha D, Madden BJ, Walsh PN, et al. The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin. J Biol Chem 2010;285:1939- 49.
34. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998;4:909-14. (Pubitemid 28364029)
35. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006;10:355-62. (Pubitemid 44693468)
36. Black PC, Mize GJ, Karlin P, Greenberg DL, Hawley SJ, True LD, et al. Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate 2007;67:743-56. (Pubitemid 46709443)
37. Kaushal V, Kohli M, Dennis RA, Siegel ER, Chiles WW, Mukunyadzi P. Thrombin receptor expression is upregulated in prostate cancer. Prostate 2006;66:273-82. (Pubitemid 43191227)
38. Mize GJ, Wang W, Takayama TK. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 Prostate cancer cells through protease-activated receptors-1 and -2. Mol Cancer Res 2008;6:1043-51.
39. Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004;2:395-402. (Pubitemid 39031073)
40. Greenberg DL, Mize GJ, Takayama TK. Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP Cells. Biochemistry 2002;42:702-9. (Pubitemid 36133294)
41. Knecht W, Cottrell GS, Amadesi S, Mohlin J, Skaregarde A, Gedda K, et al. Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia. J Biol Chem 2007;282:26089-100. (Pubitemid 47443803)
42. Grishina Z, Ostrowska E, Halangk W, Sahin-Toth M, Reiser G. Activity of recombinant trypsin isoforms on human proteinase-activated receptors (PAR): mesotrypsin cannot activate epithelial PAR-1, -2, but weakly activates brain PAR-1. Br J Pharmacol 2005;146:990 - 9.
43. Nakanishi J, Yamamoto M, Koyama J, Sato J, Hibino T. Keratinocytes synthesize enteropeptidase and multiple forms of trypsinogen during terminal differentiation. J Invest Dermatol 2010;130:944-52.
44. Nyaruhucha CN, Kito M, Fukuoka SI. Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance. J Biol Chem 1997;272:10573-8. (Pubitemid 27181064)
45. Wiegand U, Corbach S, Minn A, Kang J, Muller-Hill B. Cloning of the cDNA encoding human brain trypsinogen and characterization of its product. Gene 1993;136:167-75. (Pubitemid 24049235)
46. Rowen L, Williams E, Glusman G, Linardopoulou E, Friedman C, Ahearn ME, et al. Interchromosomal segmental duplications explain the unusual structure of PRSS3, the gene for an inhibitor-resistant trypsinogen. Mol Biol Evol 2005;22:1712-20. (Pubitemid 41373582)
47. Liu XF, Xiang L, Zhang Y, Becker KG, Bera TK, Pastan I. CAPC negatively regulates NF-kappaB activation and suppresses tumor growth and metastasis. Oncogene 2012;31:1673-82.
48. Cudic M, Fields GB. Extracellular proteases as targets for drug development. Curr Protein Peptide Sci 2009;10:297-307.
49. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006;5:785-99. (Pubitemid 44323703)
50. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30. (Pubitemid 37361545)
51. Overall CM, Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39. (Pubitemid 43292566)
52. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92. (Pubitemid 34270240)
53. Fingleton B. MMPs as therapeutic targets-still a viable option? Semin Cell Dev Biol 2008;19:61-8. (Pubitemid 350235985)
54. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-90. (Pubitemid 39472954)
55. Borgono CA, Michael IP, Shaw JL, Luo LY, Ghosh MC, Soosaipillai A, et al. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 2007;282:2405-22. (Pubitemid 47076761)
56. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-8. (Pubitemid 47463671)
57. Katona G, Berglund GI, Hajdu J, Graf L, Szilagyi L. Crystal structure reveals basis for the inhibitor resistance of human brain trypsin. J Mol Biol 2002;315:1209-18. (Pubitemid 34729298)
58. Rinderknecht H, Renner IG, Abramson SB, Carmack C. Mesotrypsin: a new inhibitor-resistant protease from a zymogen in human pancreatic tissue and fluid. Gastroenterology 1984;86:681-92. (Pubitemid 14164721)
59. Szmola R, Kukor Z, Sahin-Toth M. Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors. J Biol Chem 2003;278:48580-9. (Pubitemid 41079496)